|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||78.25 / 95.00|
The French drugs maker lead gainers in the Paris market after profits beat analyst consensus by about 13%.
New drug launches and late stage trials will be under the microscope as eight European pharmaceuticals companies report Q1 earnings starting next week.
Investors are discounting U.S. political risk and a mature economic cycle that will weigh on company earnings, said the French broker which expects a 'material pullback' in 2017.
The chances of the French drug company muscling in on Johnson & Johnson's talks with Actelion are slim, based on Sanofi's cost of capital vs. return from a possible deal.
The thwarted Medivation bidder lifts its full-year earnings estimates and announces a share buyback program.
Slower declines in diabetes drug sales and an acceleration in new oncology treatment Praluent are key to a good quarter for the French drugs maker.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.